SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-097315
Filing Date
2023-08-31
Accepted
2023-08-31 17:20:56
Documents
15
Period of Report
2023-08-31
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2317653d11_8k.htm   iXBRL 8-K 29085
2 EXHIBIT 5.1 tm2317653d11_ex5-1.htm EX-5.1 9289
7 GRAPHIC tm2317653d11_ex5-1img001.jpg GRAPHIC 4536
  Complete submission text file 0001104659-23-097315.txt   266368

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20230831.xsd EX-101.SCH 3303
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20230831_def.xml EX-101.DEF 26897
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20230831_lab.xml EX-101.LAB 36508
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20230831_pre.xml EX-101.PRE 25521
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2317653d11_8k_htm.xml XML 4906
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 231229574
SIC: 2834 Pharmaceutical Preparations